Yahoo Finance

STEALTH BIOTHERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME

"We appreciate FDA's recent recognition of the seriousness of Barth syndrome and the unmet need for potential therapies, and its commitment to complete its review of our NDA resubmission as ...
VentureBeat

Stealth Security Named a Cool Vendor in Application and Data Security by Gartner

Stealth Security recognized for being innovative, impactful, and intriguing in application and data security MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–May 10, 2018– Stealth Security, an innovator in the ...
Nasdaq

Unisys Stealth® Integrates New Microsoft Application Program Interface to Provide Uninterrupted Security for Critical Workloads in Microsoft Azure

BLUE BELL, Pa., Sept. 30, 2019 /PRNewswire/ -- Unisys Corporation (NYSE: UIS) today announced that its award-winning Unisys Stealth® security software suite now leverages the new Microsoft Azure ...
FierceBiotech

Stealth's not so sneaky strategy to file unprepared drug application foiled by FDA

It was a bold strategy, filing a drug the FDA clearly said was not ready for prime time, but Stealth BioTherapeutics did it anyway. Today, its chickens have come home to roost. The FDA has rejected ...
Medindia

STEALTH BIOTHERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME

NEEDHAM, Mass., Aug. 18, 2025 /PRNewswire/ -- Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for ...